Trial reportEndocrine2012
The role of pro/anti-inflammatory adipokines on bone metabolism in NAFLD obese adolescents: effects of long-term interdisciplinary therapy.
Trial report in Endocrine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 3 syntheses or guidelines pooled it, 79 citations in OpenAlex.
- Effects of interventions with a physical activity component on bone health in obese children and adolescents: a systematic review and meta-analysis.Journal of bone and mineral metabolism · 2018Pooled it
- NASPGHAN Clinical Practice Guideline for the Diagnosis and Treatment of Nonalcoholic Fatty Liver Disease in Children: Recommendations from the Expert Committee on NAFLD (ECON) and the North American Society of Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN).Journal of pediatric gastroenterology and nutrition · 2017Guideline
- The association between metabolic syndrome and bone mineral density: a meta-analysis.Endocrine · 2012Pooled it
- Metabolic syndrome in postmenopausal women with osteoporosis and its relationship with bone density and turnover markers.Reumatologia · 2025Article
- Review
- Synergistic Effect of β-Cryptoxanthin and Epigallocatechin Gallate on Obesity Reduction.Nutrients · 2024Article
- Fat as a Friend or Foe of the Bone.Current osteoporosis reports · 2024Review
- The association of Neuromedin U levels and non-alcoholic fatty liver disease: A comparative analysis.Heliyon · 2024Article
- Not Only Metabolic Complications of Childhood Obesity.Nutrients · 2024Review
- Synergic Action of Systemic Risedronate and Local Rutherpy in Peri-implantar Repair of Ovariectomized Rats: Biomechanical and Molecular Analysis.International journal of molecular sciences · 2023Article
- Article
- Non-pharmacological management options for MAFLD: a practical guide.Therapeutic advances in endocrinology and metabolism · 2023Review
- The association of nonalcoholic fatty liver disease with bone mineral density in type 2 diabetes.European journal of medical research · 2022Article
- The Role of Macronutrients in the Pathogenesis, Prevention and Treatment of Non-Alcoholic Fatty Liver Disease (NAFLD) in the Paediatric Population-A Review.Life (Basel, Switzerland) · 2022Review
- Non-alcoholic fatty liver disease in obese children and adolescents: a role for nutrition?European journal of clinical nutrition · 2022Review
- The Influence of Obesity, Ovariectomy, and Greenshell Mussel Supplementation on Bone Mineral Density in Rats.JBMR plus · 2022Article
- Standardised Outcome Reporting for the Nutrition Management of Complex Chronic Disease: A Rapid Review.Nutrients · 2021Review
- Association Between Liver Fat and Bone Density is Confounded by General and Visceral Adiposity in a Community-Based Cohort.Obesity (Silver Spring, Md.) · 2021Article
- Direct and Indirect Effect of Honey as a Functional Food Against Metabolic Syndrome and Its Skeletal Complications.Diabetes, metabolic syndrome and obesity : targets and therapy · 2021Review
- Prevalence and Trends in Low Bone Density, Osteopenia and Osteoporosis in U.S. Adults With Non-Alcoholic Fatty Liver Disease, 2005-2014.Frontiers in endocrinology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To investigate the role of pro- and anti-inflammatory adipokines in the bone metabolism of non-alcoholic fatty liver disease (NAFLD) obese adolescents as well as the effects of long-term interdisciplinary therapy on metabolic-related risk factors. Forty post-puberty obese adolescents were randomly assigned into two groups: (1) NAFLD group and (2) non-NAFLD group (diagnosis by ultrasonography) and submitted to a weight loss therapy. Body composition was analyzed by air displacement plethysmography, bone mineral density (BMD) and content by dual-energy X-ray absorptiometry, blood samples were collected to measure lipid profile, hepatic enzymes, and adipokines. Leptin and adiponectin concentrations were measured by ELISA. A decrease in total body mass, BMI, body fat, visceral and subcutaneous fat, insulin concentration, HOMA-IR, total cholesterol and an increase in lean body mass were observed in both groups after therapy. It was found positive correlation between the Δ BMD and the Δ fat mass (%) (r = 0.31, P = 0.01) and negative correlations between Δ BMC with Δ HOMA-IR (r = -0.34, P = 0.02) and Δ HOMA-IR with Δ leptin (r = -0.34, P = 0.02). In addition, increased levels of adiponectin and reduction in leptin concentrations were observed in NAFLD group. In the simple regression analysis, the HOMA-IR was an independent predictor changes in BMC in total obese adolescents and in the non-NAFLD group. One year of interdisciplinary weight loss therapy for obese adolescents with or without NAFLD, could regulate bone mineral metabolism as result of an increased BMC and improved inflammatory state.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.